Trial
NCT00642694
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Takeda Pharmaceuticals North America, Inc.
Condition
Major Depressive Disorder
Intervention
Escitalopram
Why stopped
Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-26